Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B
NCT00376259Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- Aug 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 5
01
Overview
A Phase 3 trial of telbivudine in hepatitis B (HBV), sponsored by Novartis. Started Jan 2007; status: terminated.
02
Drugs
telbivudine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00376259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376259.